Back to Agenda
Session 3: Asia's Role in Drug Development: A Global and Regional Perspective
Session Chair(s)
Romi Singh, PHD
Professor of Practice, Regulatory Sciences, Northeastern University, United States
Tomas Salmonson, DrMed, PHD
, Critical Path Institute, Netherlands
Historically, drug registrations in Asia followed, and to a large extent depended on, the Western drug development. However, over the recent years, there has been an increasing trend of Asia becoming a hub of global drug innovation and development. This session will discuss how Asia contributes to the global drug development and provide examples of how data generated primarily in Asia is used for registration in the West (US, EU).
Speaker(s)
Yoshimasa Shimoto, PHD
Vice President, Asia Development (Region Head), Daiichi Sankyo Co., Ltd., Japan
Contribution of Asia in Execution of Global Clinical Trials
Tomas Salmonson, DrMed, PHD
, Critical Path Institute, Netherlands
Asia's Role in Drug Development - an European Perspective
Raymond S.B. Chua, MD, MBA, MPH, FRCP
Deputy Director of Medical Services, Health Regulation Group , Ministry of Health, Singapore
Concept of Adaptive Licensing and Its Feasibility for a New Pathway of Drug Development from the Regional and Global Regulators' Perspective
Have an account?